Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) yesterday and set a price target of $29.00. The company’s shares closed yesterday at $15.71.
Matteis covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, BioMarin Pharmaceutical, and Alkermes. According to TipRanks, Matteis has an average return of 6.9% and a 44.98% success rate on recommended stocks.
Currently, the analyst consensus on Contineum Therapeutics, Inc. Class A is a Strong Buy with an average price target of $28.00, implying a 78.23% upside from current levels. In a report released on May 16, RBC Capital also assigned a Buy rating to the stock with a $30.00 price target.
The company has a one-year high of $16.09 and a one-year low of $13.27. Currently, Contineum Therapeutics, Inc. Class A has an average volume of 127.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Contineum Therapeutics, Inc. Class A (CTNM) Company Description:
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Read More on CTNM:
